Sulodexide

Generic Name: Sulodexide

Brand Names: -

Drug Type: Biotech

Chemical Formula: -

CAS Number: 57821-29-1

Unique Ingredient Identifier: 75HGV0062C

Background: Sulodexide is a mixture of glycosaminoglycans (GAGs) composed of dermatan sulfate (DS) and fast moving heparin (FMH).

Indication: Sulodexide has been used clinically for the prophylaxis and treatment of vascular diseases with increased risk of thrombosis, including intermittent claudication, peripheral arterial occlusive disease and post-myocardial infarc-tion. Also investigated in the treatment of diabetic kidney disease and diabetic neuropathy. New anti-inflammatory properties have a...

Associated Conditions: Venous Leg Ulcer (VLU), Chronic Venous Ulcers

Associated Therapies: -

Clinical Trials

The Study of Reducing Adverse Effects After Radiofrequency Ablation Combined With Sclerotherapy

Not Applicable

Not yet recruiting

Conditions: Vascular Diseases, Peripheral
Venous Insufficiency of Leg
Varicose Veins of Lower Limb

Interventions: Drug: Sulodexide

First Posted Date: 2022-12-16

Last Posted Date: 2023-01-03

Lead Sponsor: Chengdu University of Traditional Chinese Medicine

Target Recruit Count: 120

Registration Number: NCT05654233

Locations: 🇨🇳
Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China

Endothelial Protection in Post COVID-19 Patients With Sulodexide

Phase 3

Completed

Conditions: Thrombosis
Post COVID-19
Endothelial Dysfunction

Interventions: Drug: Sulodexide

First Posted Date: 2022-05-12

Last Posted Date: 2024-08-09

Lead Sponsor: Centro Medico del Noroeste

Target Recruit Count: 206

Registration Number: NCT05371925

Locations: 🇲🇽
Centro Medico del Noroeste, San Luis Rio Colorado, Sonora, Mexico

Endothelial Protection in Convalescent COVID-19 Patients

Phase 4

Conditions: COVID-19
Endothelial Dysfunction
Inflammation
Thrombosis

Interventions: Drug: Sulodexide

First Posted Date: 2022-02-23

Last Posted Date: 2022-04-22

Lead Sponsor: Pirogov Russian National Research Medical University

Target Recruit Count: 30

Registration Number: NCT05252923

Locations: 🇷🇺
Moscow Clinical Hospital no.24, Moscow, Russian Federation

Suloexide in the Treatment of Early Stages of COVID-19

Phase 2

Completed

Conditions: Covid19

Interventions: Drug: Placebo
Drug: Sulodexide

First Posted Date: 2020-07-23

Last Posted Date: 2020-09-09

Lead Sponsor: Clinedem

Target Recruit Count: 243

Registration Number: NCT04483830

Locations: 🇲🇽
Clinedem, San Luis Rio Colorado, Sonora, Mexico

Sulodexide, VESSEL®, for the Prevention of Recurrent Venous Thromboembolism (The Jason Study)

Phase 3

Recruiting

Conditions: Venous Thromboembolism
Anticoagulant
Elderly

Interventions: Drug: Sulodexide and placebo
Drug: Placebo
Drug: Sulodexide

First Posted Date: 2020-02-06

Last Posted Date: 2024-07-31

Lead Sponsor: Arianna Anticoagulazione Foundation

Target Recruit Count: 1455

Registration Number: NCT04257487

Locations: 🇮🇹
Corrado Lodigiani, Rozzano, Italy

Rotation for Optimal Targeting of Albuminuria and Treatment Evaluation (ROTATE-2)

Phase 4

Withdrawn

Conditions: Diabetic Nephropathy Type 2

Interventions: Drug: Linagliptin
Drug: Empagliflozin
Drug: Telmisartan
Drug: Sulodexide

First Posted Date: 2018-04-20

Last Posted Date: 2018-09-14

Lead Sponsor: Steno Diabetes Center Copenhagen

Registration Number: NCT03504566

Locations: 🇩🇰
Steno Diabetes Center Copenhagen, Gentofte, Denmark

Endothelial Function Evaluation in Patients With PAOD Treated With Sulodexide + Conventional Treatment (CT) Vs CT Alone

Phase 3

Conditions: Peripheral Arterial Obstructive Disease

Interventions: Drug: Statin
Drug: Sulodexide
Drug: Antiplatelet Agents
Drug: ACE inhibitor

First Posted Date: 2017-12-12

Last Posted Date: 2019-12-02

Lead Sponsor: Alfa Wassermann Tunisia

Target Recruit Count: 156

Registration Number: NCT03370705

Locations: 🇹🇳
InvSite Poseidon 0022, Sousse, Tunisia
🇹🇳
InvSite Poseidon0031, Sfax, Tunisia
🇹🇳
InvSite Poseidon0011, Tunis, Tunisia

Sulodexide Efficacy in Chronic Idiopathic Subjective Tinnitus

Phase 2

Completed

Conditions: Tinnitus, Subjective

Interventions: Drug: Placebo
Drug: Sulodexide

First Posted Date: 2016-04-14

Last Posted Date: 2017-09-14

Lead Sponsor: St Joseph University, Beirut, Lebanon

Target Recruit Count: 126

Registration Number: NCT02737670

Locations: 🇱🇧
St Jospeh University, Beirut, Lebanon

Prospective Evaluation of the QoL of Patients With PTS Who Receive Compression Therapy and Sulodexide

Phase 4

Terminated

Conditions: Post-thrombotic Syndrome

Interventions: Drug: Sulodexide
Other: Compression therapy

First Posted Date: 2015-07-31

Last Posted Date: 2017-08-31

Lead Sponsor: Bama GeVe, S.L.U.

Target Recruit Count: 13

Registration Number: NCT02512601

Locations: 🇪🇸
Hospital Espirit Sant de Santa Coloma, Santa Coloma de Gramanet, Barcelona, Spain
🇪🇸
Hospital de Cabueñes, Gijón, Asturias, Spain
🇪🇸
Complejo Hospitalario Universitario de Albacete, Albacete, Castilla la Mancha, Spain

and more 14 locations

Diabetic Retinopathy Sulodexide Study

Phase 2

Completed

Conditions: Diabetic Retinopathy

Interventions: Drug: sulodexide

First Posted Date: 2011-02-15

Last Posted Date: 2012-11-06

Lead Sponsor: Ajou University School of Medicine

Target Recruit Count: 127

Registration Number: NCT01295775

Locations: 🇰🇷
Kangnam Sacred Heart Hospital, Colloge of Medicine, Hallym University, Seoul, Korea, Republic of

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy